Table 1. A summary of 78 cases reported of large cell neuroendocrine cervical carcinoma (current case included).
| First author (No. of cases) |
Age | Stage | Treatment (No. of cases) |
Outcome (No. of cases) |
|---|---|---|---|---|
| Gilks (12) | 36–38 | IA2 | RH(1) | 36+mo (1) |
| RH with Chemo (1) | NA(1) | |||
| 21–36 | IB | RH (1) | 24 mo(1) | |
| RH+ Chemo (6) | 8–12mo(3), 6+−36+mo (3) | |||
| RH + Chemo +RT(2) | 18–24 mo(2) | |||
| 62 | IIA | RH | 6mo | |
| Tsou (1) | 35 | IIB | Chemo+RT | 18mo (1) |
| Yun (1) | 31 | IA1 | RH | 10+mo (1) |
| Krivak (2) | 25 | IB | RH; chemo for met | 35mo (1) |
| 36 | IIA | RH+ Chemo | 33mo (1) | |
| Cui (1) | 35 | NA | Neoadjuvant Chemo+ RH | NA |
| Rhemtula (5) | 55 | IIB | None (1) | 1+mo (1) |
| (South Africa) | 75 | IIIB | RT (1) | 3mo (1) |
| 51–65 | IVB | None (1) | 0.25mo (1) | |
| RT (1) | 1mo (1) | |||
| 42 | NA | None (1) | NA (1) | |
| Grayson (12) | 42–72 | NA | NA | NA |
| Wen (1) | 57 | IIB | TAHBSO+ RT | 41mo (1) |
| Dikmen (1) | 45 | IIB | TAHBSO+ RT+ Chemo | NA |
| Sato (6) | 27–51 | IB | TAHBSO+RT+ Chemo(5) | 12+−151+mo (2) |
| 16–19mo(3) | ||||
| 42 | IIA | TAHBSO+RT+ Chemo(1) | 6mo (1) | |
| Kumar (1) | 39 | IV | NA | NA |
| Baykal (1) | 38 | IB | TAHBSO+ Chemo+ RCT | 21+mo (1) |
| Tangjitgamol (6) | NA | I | NA (5) | NA (6) |
| II | NA (1) | |||
| Kawauchi (1) | 40 | IB | TAHBSO | 9mo+ (1) |
| Cetiner (1) | 47 | IIB | TAHBSO+ RT | 6mo+ (1) |
| Wang (4) | 42+/− | IA2 | RT+ Chemo (1) | NA |
| 11.3 | IB1 | RT+ Chemo (3) | ||
| Ko (1) | 45 | IB | RH+RT+ Chemo | 24mo+ (1) |
| Tangjitgamol (1) | 42 | III | Chemo | 44mo (1) |
| McCluggage (3) | 72 | I | RT+ Chemo | NA (1) |
| 32 | IIB | TAHBSO+RT+ Chemo | 17mo (1) | |
| 48 | IVB | RT+ Chemo | NA (1) | |
| Saavedra (2) | 25–42 | IB | RT+ Chemo (2) | 36+−60+mo (2) |
| Powell (1) | 31 | IIIB | TAHBSO+RT+ Chemo | NA |
| Kajiwara (2) | 55 | IIA | NA | 12mo (1) |
| 37 | IIIB | NA | 21mo (1) | |
| Li (1) | 30 | IIB | RT+ Chemo | 23mo+ (1) |
| Wang (7) | 37 | IA2 | RH+ Chemo (1) | 17.2mo (1) |
| 28–48 | IB1 | RH (1) | 114.3+mo (1) | |
| RH+ Chemo (2) | 3–17.2mo (2) | |||
| RH+ Chemo+ RT(1) | 39mo (1) | |||
| 41–62 | IB2 | RH (1) | 7mo (1) | |
| BSH+ Chemo+ RT(1) | 11.8mo (1) | |||
| Markopoulos (1) | 60 | NA | RH+ Chemo+ RT | 18mo (1) |
| Brown (1) | 40 | IVB | Chemo | NA |
| Embry (1) | 24 | IB2 | RH+ Chemo+ RT | 47mo+ |
| Yoseph (1) (current study) |
33 | IB | TAHBSO+Chemo | 24 months |
RT, radiotherapy; RCH, radio-chemotherapy; Chemo, chemotherapy; RH, radical hysterectomy; BSO, bilateral salpingo-oophorectomy; TAHBSO, Total hysterectomy with bilateral salpingo-oophorectomy; NA, not available; in outcome, + indicates being alive/censored, otherwise died.